Stockscreener 앱 받기
0.64
0.76%
0.0048
전일 마감가:
$0.6352
열려 있는:
$0.6399
하루 거래량:
18,096
Relative Volume:
0.18
시가총액:
$17.85M
수익:
$8.59M
순이익/손실:
$-17.07M
주가수익비율:
-1.0492
EPS:
-0.61
순현금흐름:
$-21.90M
1주 성능:
-0.70%
1개월 성능:
+20.46%
6개월 성능:
-14.67%
1년 성능:
-51.15%
1일 변동 폭
$0.6399
$0.6651
1주일 범위
$0.60
$0.6669
52주 변동 폭
$0.4801
$1.74
Durect Corp Stock (DRRX) Company Profile
명칭
Durect Corp
전화
(408) 777-1417
주소
10240 BUBB ROAD, CUPERTINO, CA
DRRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.64 | 17.85M | 8.59M | -17.07M | -21.90M | -0.61 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-10-30 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-12 | 개시 | ROTH Capital | Buy |
| 2020-07-31 | 개시 | Oppenheimer | Outperform |
| 2020-01-31 | 개시 | B. Riley FBR | Buy |
| 2019-11-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-06 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2017-10-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-10-20 | 재확인 | Laidlaw | Buy |
| 2017-10-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2017-02-28 | 재개 | H.C. Wainwright | Buy |
| 2016-04-25 | 개시 | Rodman & Renshaw | Buy |
| 2015-05-01 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-05-01 | 재확인 | Stifel | Buy |
| 2013-03-25 | 개시 | Stifel | Buy |
| 2012-11-01 | 다운그레이드 | C.K. Cooper | Buy → Hold |
| 2012-08-17 | 개시 | C.K. Cooper | Buy |
| 2009-06-23 | 개시 | Caris & Company | Buy |
| 2009-03-26 | 개시 | Wedbush Morgan | Hold |
모두보기
Durect Corp 주식(DRRX)의 최신 뉴스
Allay’s $57.5M extends postsurgical pain relief with ATX-101 - BioWorld MedTech
Jane Street Group LLC Purchases 28,486 Shares of DURECT Co. (NASDAQ:DRRX) - Defense World
Durect Corp stock hits 52-week low at $0.52 amid market challenges - Investing.com Australia
Durect Corp stock hits 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa
Durect says on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014 - Reuters
DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com - Defense World
Durect: Q1 Earnings Snapshot - New Haven Register
DURECT (DRRX) Q1 Revenue Surpasses Estimates, Focuses on Phase 3 Trial Funding | DRRX Stock News - GuruFocus
Durect Corp Q1 2025 Earnings: EPS at -$0.13 Misses Estimate, Rev - GuruFocus
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
DURECT (DRRX) Expected to Announce Quarterly Earnings on Monday - Defense World
Durect Corp stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Durect Corp stock hits 52-week low at $0.69 amid market challenges - Investing.com
Form 8-KCurrent report - ADVFN
DURECT Co. (NASDAQ:DRRX) Sees Large Decline in Short Interest - Defense World
DURECT (NASDAQ:DRRX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
Durect Corp stock hits 52-week low at $0.7 amid market challenges - Investing.com Canada
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call Transcript - MSN
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation - Yahoo Finance
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential - TipRanks
Durect Corp Q4 2024 Earnings: EPS of $0.25 Surpasses Estimates, Revenue Falls Short at $0.5 Million - GuruFocus
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges - Yahoo Finance
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic F - GuruFocus.com
Durect: Q4 Earnings Snapshot - MySA
Durect reports Q4 cont ops EPS (6c), consensus (2c) - TipRanks
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Durect’s Q4 2024 revenue drops as focus shifts to key drug - Investing.com India
DURECT Corp reports results for the quarter ended December 31Earnings Summary - TradingView
DURECT Transforms Business: $17.5M Asset Sale, NEJM Evidence Validates Key Drug Program - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire
What To Expect From Durect Corp (DRRX) Q4 2024 Earnings - GuruFocus
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - Quantisnow
Durect Corp (DRRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
0.60%
자본화:
|
볼륨(24시간):